Table 1.
Characteristics of patients with NSCLC according to Anti-EGFR pretreatment
| All NSCLC Patients (n=16) |
Anti-EGFR pretreated (n=10) |
No Anti-EGFR pretreatment (n=6) |
p | |
|---|---|---|---|---|
| Age, (Mean±SD (Median, [IQR])), year |
59.3±13.7 (58.5 [51.5- 70.3]) |
58.9±16.9 (57.0 [49.3- 74.0]) |
59.8±7.0 (60.0 [54.0- 63.8]) |
0.96 |
| Male, n(%) | 6 (37%) | 3 (30%) | 3 (50%) | 0.44 |
| Female, n(%) | 10 (63%) | 7 (70%) | 3 (50%) | |
| ECOG status | ||||
| 0 | 6 (38%) | 3 (30%) | 3 (50%) | 0.44 |
| 1 | 9 (56%) | 6 (60%) | 3 (50%) | 0.71 |
| 2 | 1 (6%) | 1 (10%) | 0 | 1.00 |
| EGFR Mutation status | ||||
| +ve | 1 (6%) | 1 (10%) | 0 (0%) | 1.00 |
| −ve | 13 (86%) | 7 (70%) | 6 (100%) | 0.25 |
| Not done | 2 (13%) | 2 (20%) | 0 (100%) | 0.50 |
| KRAS Mutation status | ||||
| +ve | 8 (50%) | 5 (50%) | 3 (50%) | 1.00 |
| −ve | 4 (25%) | 3 (30%) | 1 (17%) | 1.00 |
| Not done | 4 (25%) | 2 (20%) | 2 (33%) | 0.60 |
| Prior Chemotherapies (Mean±SD (Median, [IQR])) |
3.4±2.4 (3.0 [2.0-4.3]) |
3.6±2.3 (3.5 [2.3-4.8]) |
3.2±2.6 (3.0 [2.3-3.0]) |
0.58 |
ECOG: Eastern Cooperative Oncology Group, IQR: inter-quartile range